留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

特发性Evans综合征复发后确诊为小B淋巴细胞淋巴瘤一例

刘琰婷 张路 陈苗 张炎 魏冲 潘伯驹 赵甲维

刘琰婷, 张路, 陈苗, 张炎, 魏冲, 潘伯驹, 赵甲维. 特发性Evans综合征复发后确诊为小B淋巴细胞淋巴瘤一例[J]. 协和医学杂志, 2021, 12(3): 423-426. doi: 10.12290/xhyxzz.20200063
引用本文: 刘琰婷, 张路, 陈苗, 张炎, 魏冲, 潘伯驹, 赵甲维. 特发性Evans综合征复发后确诊为小B淋巴细胞淋巴瘤一例[J]. 协和医学杂志, 2021, 12(3): 423-426. doi: 10.12290/xhyxzz.20200063
LIU Yanting, ZHANG Lu, CHEN Miao, ZHANG Yan, WEI Chong, PAN Boju, ZHAO Jiawei. A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 423-426. doi: 10.12290/xhyxzz.20200063
Citation: LIU Yanting, ZHANG Lu, CHEN Miao, ZHANG Yan, WEI Chong, PAN Boju, ZHAO Jiawei. A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 423-426. doi: 10.12290/xhyxzz.20200063

特发性Evans综合征复发后确诊为小B淋巴细胞淋巴瘤一例

doi: 10.12290/xhyxzz.20200063
基金项目: 

国家自然科学基金 81900202

中央高校基本科研业务费 3332018036

详细信息
    通讯作者:

    张路 电话:010-69155001,E-mail: pumczhanglu@126.com

  • 中图分类号: R825.5; R593.2

A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome

Funds: 

Natural Science Foundation of China 81900202

Fundamental Research Funds for the Central Universities 3332018036

More Information
  • 摘要: Evans综合征是指同时或相继发生自身免疫性溶血性贫血和免疫性血小板减少症,依据病因可分为原发性和继发性两种,其中血液系统恶性肿瘤是较为常见的继发因素。现报道1例特发性Evans综合征病例,首次起病时排除了可能的继发因素,经利妥昔单克隆抗体联合硼替佐米治疗后病情改善,1年后再次发病并最终确诊为小B淋巴细胞淋巴瘤,提示对于复发或难治性Evans综合征,应仔细筛查相关继发因素。本文通过分析此患者疾病复发过程、实验室检查结果、诊治经过,以期为临床医师诊治该类疾病提供帮助。
    作者贡献: 刘琰婷负责收集资料,撰写文章;张路负责审阅文章,提供经费、技术或材料支持;陈苗、张炎负责审阅文章;魏冲、潘伯驹负责审阅文章,提供材料支持;赵甲维负责收集资料,起草文章。
    利益冲突  无
  • 图  1  骨髓活检病理结果

    A.CD20免疫组化染色,可见弥漫阳性(×200);B.CD5免疫组化染色,+/-(×200);C.CD23免疫组化染色,可见弥漫阳性(×200)

  • [1] Hill QA. Autoimmune hemolytic anemia[J]. Hematology, 2015, 20: 553-554. doi:  10.1179/1024533215Z.000000000401
    [2] Penalver FJ, Alvarez-Larran A, Diez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia[J]. Ann Hematol, 2010, 89: 1073-1080. doi:  10.1007/s00277-010-0997-y
    [3] Ratnasingam S, Walker PA, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases[J]. Blood Adv, 2016, 1: 31-35. doi:  10.1182/bloodadvances.2016001412
    [4] Muhsen IN, Alahmari A, Alnahedh M, et al. Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia[J]. Hematol Oncol Stem Cell Ther, 2019, S1658-3876: 30051-30052. http://www.sciencedirect.com/science/article/pii/S1658387619300512
    [5] Chen M, Zhuang JL, Yang C, et al. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia[J]. Ann Hematol, 2020, 99: 1141-1143. doi:  10.1007/s00277-020-03976-w
    [6] Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features[J]. Blood, 2000, 95: 2786-2792. doi:  10.1182/blood.V95.9.2786.009k30_2786_2792
    [7] 郑雪娜, 魏锦, 谭竞. 慢性淋巴细胞白血病相关性自身免疫性溶血性贫血的发病机制[J]. 中国临床医学, 2011, 18: 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201101046.htm

    Zheng XN, Wei J, Tan J. Mechanisms about chronic lymphocytic leukemia-associated autoimmune hemolytic anemia[J]. Zhongguo Lin Chuang Yi Xue, 2011, 18: 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201101046.htm
    [8] Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance[J]. Blood, 2010, 116: 4771-4776. http://europepmc.org/abstract/MED/20736453
    [9] Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma[J]. Br J Haematol, 2008, 141: 615-621. doi:  10.1111/j.1365-2141.2008.07086.x
    [10] Jaime-Pérez JC, Aguilar-Calderón PE, Salazar-Cavazos L, et al. Evans syndrome: clinical perspectives, biological insights and treatment modalities[J]. J Blood Med, 2018, 9: 171-184. doi:  10.2147/JBM.S176144
    [11] Hauswirth AW, Skrabs C, Schützinger C, et al. Autoim-mune hemolytic anemias, Evans' syndrome, and pure red cell aplasia in non-Hodgkin lymphomas[J]. Leuk Lymphoma, 2007, 48: 1139-1149. doi:  10.1080/10428190701385173
  • 加载中
图(1)
计量
  • 文章访问数:  98
  • HTML全文浏览量:  23
  • PDF下载量:  22
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-03-05
  • 录用日期:  2020-04-15
  • 网络出版日期:  2021-02-01
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回